Biology & biomedicine Success stories
The first nano drug for selectively fighting metastatic cells
- Details
- Category: Success stories
-
14 Sep 2018
Scientists from the IQAC-CSIC have participated in the development and essay of a molecule for fighting colon cancer metastasis. It is the first drug worldwide that blocks metastasis dissemination, which is the main cause of mortality of oncological patients. Also, the study demonstrates that the drug is less toxic and therefore reduces the adverse effects derived from conventional treatments.
A spin-off company to design and develop preclinical assays of liver diseases
- Details
- Category: Success stories
-
19 Feb 2018
Barcelona Liver Bioservices (BLB) is a spin-off of the CSIC and IDIBAPS created to offer services of designing and developing pre-clinical assays of liver diseases and liver toxicity of compounds.
Autonomous sensor for the detection of breathing problems
- Details
- Category: Success stories
-
19 Sep 2016
Scientists from the Microelectronics Institute of Barcelona (IMB CNM – CSIC), the Universitat Autònoma de Barcelona (UAB), and the Universitat Politècnica de Catalunya (UPC) have developed an autonomous thermoelectric sensor based on silicon nanotechnology to detect flow changes. It can be applied to the detection of breathing problems.
Transgenic plants to produce drugs against malaria
- Details
- Category: Success stories
-
31 Mar 2017
A gene of the Artemisia annua plant doubles the production of artemisinin. Artemisinin-based combination therapy (ACT) is the standard treatment for malaria worldwide, endorsed by the World Health Organization (WHO). The discovery represents an important step towards reducing artemisinin production costs.
New nanodrug improves the treatment of diabetic foot ulcers
- Details
- Category: Success stories
-
12 Nov 2014
A nanomedicine developed and patented by the research group Nanomol at the Instituto de Ciencia de Materiales de Barcelona (CSIC), and by the Centro de Ingeniería Genética y Biotecnología in Cuba, will be commercialized by the company Heber Biotec. The agreement will allow the development and commercialization of a nanoformulated protein for the improved treatment of diabetic foot ulcers.
